Supplementary Table 1, Figures 1-5 from Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1, Figures 1-5. Supplemental Table 1 (Table S1) - Affinity of a bivalent antibody (IgG KD) is largely different from it monovalent form (scFv KD). Supplemental Figure 1 (Fig. S1) - Surface expression level of ErbB2 detected by flow cytometry is correlated with mRNA level detected by quantitative PCR. Supplemental Figure 2 (Fig. S2) - CD107a up-regulation was different between higher affinity ErbB2 CART cells and lower affinity CART cells when stimulated with tumor cell lines expressing ErbB2 at different levels. Supplemental Figure 3 (Fig. S3) - More tumor cell lines tested in a CD107a assay confirmed that lower affinity ErbB2 CART cells only recognized ErbB2 over expression tumors. Supplemental Figure 4 (Fig. S4) - ErbB2 target dependent upregulation of CD107a of lower affinity ErbB2 CAR lentiviral transduced, as well as lower affinity ErbB2 CAR mRNA electroporated T cells. Supplemental Figure 5 (Fig. S5) - ErbB2 CART cells with decreased affinity controlled tumor growth as efficiently as ErbB2 CART cells with higher affinity.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362291327